NRXP beat EPS expectations by 5.49%
Aug 21, 2024, 9:36 AM
0.00%
What does NRXP do
NRX Pharmaceuticals, Inc., a clinical-stage company based in Wilmington, Delaware, specializes in developing treatments for central nervous system disorders such as suicidal depression and PTSD. Key developments include Phase III trials for NRX-101 targeting bipolar depression and initiatives like NRX-100 for anesthesia and ZYESAMI for COVID-19 respiratory failures.
NRX Pharmaceuticals (NRXP) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, NRX Pharmaceuticals's actual EPS was -$0.67, beating the estimate of -$0.71 per share, resulting in a 5.49% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.